Business Description
Exact Therapeutics AS
ISIN : NO0010852213
Share Class Description:
OSL:EXTX: Ordinary SharesTotal Employee Number:
11Description
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 53.95 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -0.9 | |||||
3-Year EPS without NRI Growth Rate | -0.7 | |||||
3-Year FCF Growth Rate | -0.2 | |||||
3-Year Book Growth Rate | -39.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.44 | |||||
9-Day RSI | 48.05 | |||||
14-Day RSI | 44.18 | |||||
3-1 Month Momentum % | -50.96 | |||||
6-1 Month Momentum % | -61.31 | |||||
12-1 Month Momentum % | -74.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.65 | |||||
Quick Ratio | 1.65 | |||||
Cash Ratio | 0.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.2 | |||||
Shareholder Yield % | 0.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -121.96 | |||||
ROA % | -81.04 | |||||
ROIC % | -235.38 | |||||
3-Year ROIIC % | -197.05 | |||||
ROC (Joel Greenblatt) % | -1381.64 | |||||
ROCE % | -121.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.5 | |||||
Price-to-Tangible-Book | 1.49 | |||||
EV-to-EBIT | -0.68 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-FCF | -0.8 | |||||
| Price-to-Net-Current-Asset-Value | 1.92 | |||||
Earnings Yield (Greenblatt) % | -147.83 | |||||
FCF Yield % | -88.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exact Therapeutics AS Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.37 | ||
| Beta | 0.9114 | ||
| 3-Year Sharpe Ratio | -1.15 | ||
| 3-Year Sortino Ratio | -1.31 | ||
| Volatility % | 64.6 | ||
| 14-Day RSI | 44.18 | ||
| 14-Day ATR (kr) | 0.072015 | ||
| 20-Day SMA (kr) | 0.7385 | ||
| 12-1 Month Momentum % | -74.33 | ||
| 52-Week Range (kr) | 0.58 - 3 | ||
| Shares Outstanding (Mil) | 111.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exact Therapeutics AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exact Therapeutics AS Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-03 | In 44 days | ||
| General meeting for 2026 | 2026-06-12 10:30 | 0.71 (-2.74%) | ||
| Annual report for 2025 | 2026-04-08 | 1.69 (+5.62%) | ||
| Second quarter earnings results for 2025 | 2025-09-25 | 1.90 (-15.18%) | ||
| General meeting for 2025 | 2025-06-13 10:30 | 2.60 (-12.16%) | ||
| Annual report for 2024 | 2025-04-09 | 3.06 (+0.00%) | ||
| Second quarter earnings results for 2024 | 2024-09-30 | 5.75 (+0.00%) | ||
| 250:1 Stock Split | 2020-07-27 | 35.80 (+0.56%) |
Show
Entries
Exact Therapeutics AS Frequently Asked Questions
What is Exact Therapeutics AS(OSL:EXTX)'s stock price today?
The current price of OSL:EXTX is kr0.73. The 52 week high of OSL:EXTX is kr3.00 and 52 week low is kr0.58.
When is next earnings date of Exact Therapeutics AS(OSL:EXTX)?
The next earnings date of Exact Therapeutics AS(OSL:EXTX) is 2026-09-03.
Does Exact Therapeutics AS(OSL:EXTX) pay dividends? If so, how much?
Exact Therapeutics AS(OSL:EXTX) does not pay dividend.
Press Release
Articles on Exact Therapeutics AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers